Strongyloidiasis natural history, complications and prognosis: Difference between revisions
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Strongyloidiasis}} | {{Strongyloidiasis}} | ||
{{CMG}} ; {{AE}} {{ADG}} | |||
==Overview== | ==Overview== | ||
If strongyloidiasis is left untreated, the infection can disseminate and transform into hyper infection syndrome which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with [[HIV]] or other immunocompromised conditions), [[eosinophilic pneumonia]], [[malnutrition]], and [[malabsorption]]. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. [[Infections]] that are severe or widespread often have a poor outcome, especially in people with a suppressed immune system. | If strongyloidiasis is left untreated, the infection can disseminate and transform into hyper infection syndrome which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with [[HIV]] or other immunocompromised conditions), [[eosinophilic pneumonia]], [[malnutrition]], and [[malabsorption]]. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. [[Infections]] that are severe or widespread often have a poor outcome, especially in people with a suppressed immune system.<ref name="pmid27213420">{{cite journal |vauthors=Beknazarova M, Whiley H, Ross K |title=Strongyloidiasis: A Disease of Socioeconomic Disadvantage |journal=Int J Environ Res Public Health |volume=13 |issue=5 |pages= |year=2016 |pmid=27213420 |pmc=4881142 |doi=10.3390/ijerph13050517 |url=}}</ref> | ||
==Natural history== | ==Natural history== | ||
Revision as of 20:20, 2 August 2017
|
Strongyloidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Strongyloidiasis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Strongyloidiasis natural history, complications and prognosis |
|
FDA on Strongyloidiasis natural history, complications and prognosis |
|
CDC on Strongyloidiasis natural history, complications and prognosis |
|
Strongyloidiasis natural history, complications and prognosis in the news |
|
Blogs on Strongyloidiasis natural history, complications and prognosis |
|
Risk calculators and risk factors for Strongyloidiasis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
If strongyloidiasis is left untreated, the infection can disseminate and transform into hyper infection syndrome which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with HIV or other immunocompromised conditions), eosinophilic pneumonia, malnutrition, and malabsorption. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. Infections that are severe or widespread often have a poor outcome, especially in people with a suppressed immune system.[1]
Natural history
If left untreated, the subclinical strongyloidiasis can disseminate and transform into hyper-infection syndrome with a mortality rate of 90%.
Complications
Complications that can develop as a result of strongyloidiasis are:
- Disseminated strongyloidiasis, especially in patients with HIV or who are otherwise immunosuppressed
- Eosinophilic pneumonia
- Malnutrition due to problems absorbing nutrients from the gastrointestinal tract (malabsorption)
Prognosis
With appropriate treatment, people should make a full recovery. Sometimes, treatment needs to be repeated. Infections that are severe or widespread often have a poor outcome, especially in people with immunosuppression. Strongyloidiasis could be severe and life-threatening in specific groups including:
- Those who use of oral or intravenous steroids, for example, in patients with asthma, chronic obstructive pulmonary disease (COPD) exacerbations, lupus, gout, or in persons using steroids for immunosuppression or symptomatic relief
- Those with HTLV-1 infection
- Those with Hematologic malignancies such as leukemia or lymphoma
- Transplant recipients
Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%.
References
- ↑ Beknazarova M, Whiley H, Ross K (2016). "Strongyloidiasis: A Disease of Socioeconomic Disadvantage". Int J Environ Res Public Health. 13 (5). doi:10.3390/ijerph13050517. PMC 4881142. PMID 27213420.